Advanced

Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas

Lindén, Ola LU ; Tennvall, Jan LU ; Cavallin-Ståhl, Eva LU ; Darte, Lennart LU ; Garkavij, Michael LU ; Lindner, K J; Ljungberg, Michael LU ; Ohlsson, Tomas G LU ; Sjögreen Gleisner, Katarina LU and Wingårdh, Karin LU , et al. (1999) In Clinical Cancer Research 5(10 Suppl). p.3287-3291
Abstract
Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have measurable disease, less than 25% B cells in unseparated bone marrow, and an uptake of 99mTc-labeled LL2Fab' in at least one lymphoma lesion on immunoscintigram. Eight of nine patients examined with immunoscintigraphy were unequivocally found to have an uptake, and therapy with 131I-labeled anti-CD22 [1330 MBq/m2 (36 mCi/m2)] preceded by 20 mg of naked... (More)
Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have measurable disease, less than 25% B cells in unseparated bone marrow, and an uptake of 99mTc-labeled LL2Fab' in at least one lymphoma lesion on immunoscintigram. Eight of nine patients examined with immunoscintigraphy were unequivocally found to have an uptake, and therapy with 131I-labeled anti-CD22 [1330 MBq/m2 (36 mCi/m2)] preceded by 20 mg of naked anti-CD22 mAb was administered. Three patients achieved partial remission (duration, 12, 3, and 2 months), and one patient with progressive lymphoma showed stable disease for 17 months. Four patients exhibited progressive disease. The toxicity was hematological. Patients with subnormal counts of neutrophils or platelets before therapy seemed to be more at risk for hematological side effects. Radioimmunotherapy in patients with B-cell lymphomas using 131I-labeled mouse anti-CD22 can induce objective remission in patients with aggressive as well as indolent lymphomas who have failed prior chemotherapy. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Cancer Research
volume
5
issue
10 Suppl
pages
3287 - 3291
publisher
American Association for Cancer Research
external identifiers
  • scopus:0032589761
ISSN
1078-0432
language
English
LU publication?
yes
id
4572af62-5b6d-4913-9e51-44594c0fff41 (old id 1114495)
alternative location
http://clincancerres.aacrjournals.org/content/5/10/3287s
date added to LUP
2008-07-04 11:43:27
date last changed
2017-08-06 03:43:53
@article{4572af62-5b6d-4913-9e51-44594c0fff41,
  abstract     = {Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have measurable disease, less than 25% B cells in unseparated bone marrow, and an uptake of 99mTc-labeled LL2Fab' in at least one lymphoma lesion on immunoscintigram. Eight of nine patients examined with immunoscintigraphy were unequivocally found to have an uptake, and therapy with 131I-labeled anti-CD22 [1330 MBq/m2 (36 mCi/m2)] preceded by 20 mg of naked anti-CD22 mAb was administered. Three patients achieved partial remission (duration, 12, 3, and 2 months), and one patient with progressive lymphoma showed stable disease for 17 months. Four patients exhibited progressive disease. The toxicity was hematological. Patients with subnormal counts of neutrophils or platelets before therapy seemed to be more at risk for hematological side effects. Radioimmunotherapy in patients with B-cell lymphomas using 131I-labeled mouse anti-CD22 can induce objective remission in patients with aggressive as well as indolent lymphomas who have failed prior chemotherapy.},
  author       = {Lindén, Ola and Tennvall, Jan and Cavallin-Ståhl, Eva and Darte, Lennart and Garkavij, Michael and Lindner, K J and Ljungberg, Michael and Ohlsson, Tomas G and Sjögreen Gleisner, Katarina and Wingårdh, Karin and Strand, Sven-Erik},
  issn         = {1078-0432},
  language     = {eng},
  number       = {10 Suppl},
  pages        = {3287--3291},
  publisher    = {American Association for Cancer Research},
  series       = {Clinical Cancer Research},
  title        = {Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas},
  volume       = {5},
  year         = {1999},
}